Oral Solid Dosage Excipients Market By Product Type (Glycerin, Propylene Glycol, Sorbitol, Mannitol and Others), By Form (Crystal, Powder and Others), By Application (Industrial and Non-Industrial) and By Region - Market Trends, Analysis, and Forecast till 2030

Pharmaceuticals industries are the wide and essential industries. Excipients are a part of the pharmaceutical industry and their demand is expected to increase over the forecast period. This is due to their ability to perform various functions such as improving the modifying drug release, stability of the active pharmaceutical ingredient (API) and masking taste. Expanding patient base and developing cost-effective drugs has led to the growth of generics. Moreover, the need for excipients has increased which can be successfully utilized for these drugs. Furthermore, excipients exhibit no medicinal properties to the drug; they have a well-defined role ranging from protecting the API to easing the manufacturing process. Factors such as patent expiration of blockbuster drugs, which consequently boost the need for generic drugs, and increasing demand for patient-compliant drugs have boosted the demand for oral solid dosage excipients. However, stringent regulatory process is one of the roadblocks for the development of novel excipients. Long development process, huge investment into R&D, and chances of failure have prevented manufacturers from developing novel excipients.

Impact of Covid-19 pandemic on market

The decline in this market is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving remote working, social distancing and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disturbed, impacting the market negatively.

Increasing Demand for Environmentally Friendly Excipients to Drive the Growth of the Market

Continuous manufacturing technology has gained prominence in the market. Although traditional processes are incorporated in the continuous process line, the requirement of ingredients differs. Therefore, there is a need for excipients that are also well suited for the continuous process. Rising geriatric, children and mentally-disabled population has increased the demand for flexible oral dosage formulations including chewable tablets and lozenges.  Furthermore, with the influx of such flexible oral solid dosage formations, the demand for excipients compatible with them has subsequently increased driving the market

Difficulty and time consuming process involved for manufacturing

The oral solid doses excipient industries faces some competition from injectable doses industries because of the increasingly difficult-to-formulate Active Pharmaceutical Ingredient (APIs) in the drug pipeline.

He Global Oral Solid Dosage Excipients Market is segmented based on product type, form, application, and region. By Product Type, Global Oral Solid Dosage Excipients Market is segmented into Glycerin, Propylene Glycol, Sorbitol, Mannitol and Others. By Form, the market is segmented in Crystal, Powder and Others. By Application, Global Oral Solid Dosage Excipients Market is segmented into Industrial and Non-Industrial.

Regional Insights:

Based on region, the Global Oral Solid Dosage Excipients Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America has dominated the oral solid dosage excipients market and is expected to sustain this position during the forecast period. Furthermore, strong economic growth increases the affordability quotient, which results in an increased demand for better healthcare services in the region.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the Global Oral Solid Dosage Excipients Market report based on product type, form, application, and region.

Global Oral Solid Dosage Excipients Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the Global Oral Solid Dosage Excipients Market includes AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson and Johnson, Biogen Inc., Bayer AG, Teva Pharmaceuticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co. Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc. Companies are continuously rising the production and supply of excipient dosage. Evonik, a German specialty pharmaceuticals company, announced on Dec. 7, 2020 that it has signed an agreement to acquire the LACTEL business of biodegradable polymers from DURECT for US $15 million.

• Merck and Co. Inc.
• AstraZeneca Plc.
•  Bristol-Myers Squibb Company
•  Eli Lilly and Company
• Gilead Sciences
•  Novartis AG
•  Pfizer Inc.
•  AbbVie Inc.
•  Boehringer Ingelheim GmbH
•  Hoffman-La-Roche Ltd.
•  Johnson and Johnson
• Biogen Inc.
• Bayer AG
• Teva Pharmaceuticals
• Amgen Inc.
• Takeda Pharmaceutical Company Ltd.
•  Otsuka Pharmaceutical Co.
•  Ltd.
•  Shire Plc.
•  Celgene Corporation
• Astellas Pharma Inc.